ERNESTINA MELICOFF-PORTILLO
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Transplantation | 21 | 2024 | 337 | 5.250 |
Why?
|
| Cystic Fibrosis | 4 | 2022 | 266 | 1.470 |
Why?
|
| Lung Diseases | 2 | 2023 | 404 | 1.120 |
Why?
|
| Waiting Lists | 4 | 2024 | 241 | 1.000 |
Why?
|
| Graft Rejection | 7 | 2021 | 566 | 0.960 |
Why?
|
| Tissue and Organ Procurement | 2 | 2022 | 248 | 0.730 |
Why?
|
| Tissue Donors | 2 | 2022 | 507 | 0.710 |
Why?
|
| Vascular Diseases | 1 | 2023 | 155 | 0.710 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2020 | 22 | 0.690 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 230 | 0.630 |
Why?
|
| Education, Medical, Continuing | 1 | 2019 | 143 | 0.580 |
Why?
|
| Postoperative Complications | 4 | 2018 | 3171 | 0.570 |
Why?
|
| Bacterial Infections | 1 | 2021 | 329 | 0.560 |
Why?
|
| Bronchiolitis Obliterans | 3 | 2022 | 41 | 0.520 |
Why?
|
| Child | 25 | 2024 | 25848 | 0.490 |
Why?
|
| Bronchial Arteries | 1 | 2015 | 4 | 0.490 |
Why?
|
| Anti-Infective Agents | 1 | 2018 | 276 | 0.480 |
Why?
|
| Synaptotagmin II | 4 | 2009 | 8 | 0.480 |
Why?
|
| Organ Transplantation | 3 | 2022 | 182 | 0.450 |
Why?
|
| Exocytosis | 4 | 2009 | 66 | 0.420 |
Why?
|
| Adolescent | 16 | 2024 | 20551 | 0.390 |
Why?
|
| Lung | 6 | 2022 | 1570 | 0.390 |
Why?
|
| Mast Cells | 2 | 2009 | 71 | 0.360 |
Why?
|
| Vascular Surgical Procedures | 1 | 2015 | 563 | 0.330 |
Why?
|
| Pediatrics | 1 | 2019 | 1220 | 0.320 |
Why?
|
| Infant | 10 | 2024 | 13232 | 0.310 |
Why?
|
| Incidence | 5 | 2021 | 3393 | 0.300 |
Why?
|
| Child, Preschool | 11 | 2024 | 14862 | 0.300 |
Why?
|
| Community-Acquired Infections | 2 | 2020 | 247 | 0.280 |
Why?
|
| Transplant Recipients | 4 | 2022 | 227 | 0.280 |
Why?
|
| Retrospective Studies | 8 | 2024 | 17557 | 0.260 |
Why?
|
| Respiratory Tract Infections | 2 | 2020 | 296 | 0.260 |
Why?
|
| Humans | 31 | 2024 | 133295 | 0.240 |
Why?
|
| Viral Load | 2 | 2017 | 411 | 0.240 |
Why?
|
| Risk Factors | 9 | 2024 | 10959 | 0.220 |
Why?
|
| Heart Transplantation | 2 | 2022 | 887 | 0.220 |
Why?
|
| Survival Rate | 2 | 2023 | 2208 | 0.220 |
Why?
|
| Hypoxia | 2 | 2016 | 267 | 0.210 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 2 | 2014 | 137 | 0.200 |
Why?
|
| Atrial Flutter | 1 | 2022 | 34 | 0.190 |
Why?
|
| Heart-Lung Transplantation | 1 | 2022 | 24 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 2193 | 0.190 |
Why?
|
| Cryptococcosis | 1 | 2021 | 44 | 0.180 |
Why?
|
| Calcium | 5 | 2009 | 1104 | 0.180 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2022 | 110 | 0.180 |
Why?
|
| Ribs | 1 | 2021 | 54 | 0.180 |
Why?
|
| Symptom Assessment | 1 | 2020 | 109 | 0.170 |
Why?
|
| Picornaviridae Infections | 1 | 2020 | 52 | 0.160 |
Why?
|
| Ventricular Function | 1 | 2020 | 91 | 0.160 |
Why?
|
| Immunocompromised Host | 2 | 2020 | 305 | 0.160 |
Why?
|
| Graft Survival | 2 | 2019 | 482 | 0.160 |
Why?
|
| Postoperative Period | 1 | 2020 | 338 | 0.160 |
Why?
|
| Immunosuppressive Agents | 2 | 2021 | 679 | 0.160 |
Why?
|
| Exercise Test | 1 | 2020 | 263 | 0.160 |
Why?
|
| Idiopathic Interstitial Pneumonias | 1 | 2019 | 10 | 0.150 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 5439 | 0.150 |
Why?
|
| Hypertension, Pulmonary | 2 | 2016 | 474 | 0.150 |
Why?
|
| Pulmonary Fibrosis | 3 | 2016 | 112 | 0.150 |
Why?
|
| Certification | 1 | 2019 | 73 | 0.150 |
Why?
|
| Osteomyelitis | 1 | 2021 | 214 | 0.150 |
Why?
|
| Length of Stay | 1 | 2024 | 1394 | 0.150 |
Why?
|
| Drug Resistance, Multiple | 1 | 2018 | 52 | 0.150 |
Why?
|
| Cold Ischemia | 1 | 2018 | 23 | 0.150 |
Why?
|
| Time Factors | 4 | 2018 | 6547 | 0.150 |
Why?
|
| Perioperative Care | 1 | 2020 | 212 | 0.150 |
Why?
|
| Synaptic Transmission | 3 | 2009 | 365 | 0.140 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2021 | 234 | 0.140 |
Why?
|
| Anelloviridae | 1 | 2017 | 1 | 0.140 |
Why?
|
| Male | 18 | 2024 | 65544 | 0.140 |
Why?
|
| Operative Time | 1 | 2018 | 189 | 0.140 |
Why?
|
| Hodgkin Disease | 1 | 2020 | 295 | 0.140 |
Why?
|
| Lung Diseases, Fungal | 1 | 2017 | 32 | 0.140 |
Why?
|
| Calcium Signaling | 2 | 2009 | 257 | 0.130 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2021 | 378 | 0.130 |
Why?
|
| Interleukin-6 | 3 | 2014 | 439 | 0.130 |
Why?
|
| Pamphlets | 1 | 2016 | 24 | 0.130 |
Why?
|
| Virus Diseases | 1 | 2019 | 291 | 0.130 |
Why?
|
| United States | 3 | 2022 | 11724 | 0.130 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2018 | 359 | 0.130 |
Why?
|
| Female | 16 | 2024 | 71471 | 0.120 |
Why?
|
| Heart Ventricles | 1 | 2020 | 789 | 0.120 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2017 | 225 | 0.120 |
Why?
|
| Deoxycytidine Kinase | 1 | 2014 | 2 | 0.120 |
Why?
|
| Adenosine | 1 | 2016 | 140 | 0.120 |
Why?
|
| Atrial Fibrillation | 1 | 2022 | 699 | 0.120 |
Why?
|
| Echocardiography | 1 | 2020 | 1127 | 0.110 |
Why?
|
| Macrophages, Alveolar | 1 | 2014 | 47 | 0.110 |
Why?
|
| Bronchoscopy | 1 | 2015 | 172 | 0.110 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2014 | 44 | 0.110 |
Why?
|
| Herpesvirus 4, Human | 1 | 2017 | 674 | 0.110 |
Why?
|
| Curriculum | 1 | 2019 | 768 | 0.110 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 467 | 0.100 |
Why?
|
| Receptor, Adenosine A2B | 1 | 2012 | 11 | 0.100 |
Why?
|
| Liver Transplantation | 1 | 2021 | 1124 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 6 | 2014 | 4824 | 0.090 |
Why?
|
| Prospective Studies | 5 | 2022 | 6585 | 0.090 |
Why?
|
| Quality of Life | 1 | 2020 | 2165 | 0.080 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2012 | 176 | 0.080 |
Why?
|
| Mice, Knockout | 4 | 2014 | 3980 | 0.080 |
Why?
|
| Mice | 10 | 2014 | 18938 | 0.080 |
Why?
|
| Cells, Cultured | 3 | 2012 | 3131 | 0.080 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2009 | 137 | 0.080 |
Why?
|
| Synaptic Vesicles | 1 | 2009 | 67 | 0.080 |
Why?
|
| Presynaptic Terminals | 1 | 2009 | 83 | 0.080 |
Why?
|
| Cell Count | 1 | 2009 | 235 | 0.080 |
Why?
|
| Adult | 4 | 2022 | 31661 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 3863 | 0.070 |
Why?
|
| Endocytosis | 1 | 2009 | 134 | 0.070 |
Why?
|
| Cytoplasmic Granules | 1 | 2009 | 51 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2009 | 316 | 0.070 |
Why?
|
| Calmodulin | 1 | 2009 | 223 | 0.070 |
Why?
|
| Cell Extracts | 1 | 2008 | 13 | 0.070 |
Why?
|
| Goblet Cells | 1 | 2009 | 106 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2020 | 13104 | 0.070 |
Why?
|
| Endoplasmic Reticulum | 1 | 2009 | 230 | 0.070 |
Why?
|
| Bone Marrow Cells | 1 | 2009 | 269 | 0.070 |
Why?
|
| Young Adult | 3 | 2017 | 9925 | 0.070 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2008 | 87 | 0.070 |
Why?
|
| Tryptases | 1 | 2007 | 18 | 0.070 |
Why?
|
| Hypersensitivity | 1 | 2009 | 195 | 0.070 |
Why?
|
| Texas | 1 | 2015 | 3664 | 0.060 |
Why?
|
| Neuromuscular Junction | 1 | 2006 | 101 | 0.060 |
Why?
|
| Neurotransmitter Agents | 1 | 2006 | 150 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2008 | 391 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 1730 | 0.060 |
Why?
|
| Animals | 10 | 2014 | 36220 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2008 | 416 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 1137 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1514 | 0.050 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2017 | 155 | 0.050 |
Why?
|
| Synapses | 1 | 2006 | 470 | 0.050 |
Why?
|
| Organ Dysfunction Scores | 1 | 2022 | 52 | 0.050 |
Why?
|
| Tachycardia | 1 | 2022 | 68 | 0.050 |
Why?
|
| Interleukin-23 | 1 | 2022 | 15 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2014 | 4918 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2009 | 2027 | 0.040 |
Why?
|
| Multiple Organ Failure | 1 | 2022 | 144 | 0.040 |
Why?
|
| Respiratory Mucosa | 2 | 2014 | 98 | 0.040 |
Why?
|
| Palivizumab | 1 | 2021 | 48 | 0.040 |
Why?
|
| Rituximab | 1 | 2021 | 165 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2021 | 105 | 0.040 |
Why?
|
| Rhinovirus | 1 | 2020 | 63 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 2651 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2021 | 306 | 0.040 |
Why?
|
| Prognosis | 2 | 2019 | 5042 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2019 | 216 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 724 | 0.040 |
Why?
|
| Viruses | 1 | 2019 | 128 | 0.040 |
Why?
|
| Rats, Wistar | 2 | 2009 | 398 | 0.040 |
Why?
|
| Patient Selection | 1 | 2022 | 734 | 0.040 |
Why?
|
| Organoids | 1 | 2021 | 301 | 0.030 |
Why?
|
| Survivors | 1 | 2020 | 358 | 0.030 |
Why?
|
| Heart | 1 | 2022 | 712 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2017 | 149 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2019 | 618 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8628 | 0.030 |
Why?
|
| Vascular Remodeling | 1 | 2016 | 54 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 1965 | 0.030 |
Why?
|
| Cytokines | 1 | 2022 | 1378 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2016 | 102 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2017 | 496 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 3719 | 0.030 |
Why?
|
| Brain | 1 | 2006 | 3224 | 0.030 |
Why?
|
| Fibronectins | 1 | 2014 | 110 | 0.030 |
Why?
|
| Myofibroblasts | 1 | 2014 | 68 | 0.030 |
Why?
|
| Reoperation | 1 | 2017 | 856 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 1557 | 0.030 |
Why?
|
| Pulmonary Alveoli | 1 | 2014 | 142 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 1582 | 0.030 |
Why?
|
| Collagen | 1 | 2014 | 314 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 543 | 0.020 |
Why?
|
| Rats | 2 | 2009 | 3851 | 0.020 |
Why?
|
| Adenosine-5'-(N-ethylcarboxamide) | 1 | 2012 | 1 | 0.020 |
Why?
|
| Purinergic P1 Receptor Agonists | 1 | 2012 | 5 | 0.020 |
Why?
|
| Mice, Transgenic | 2 | 2009 | 2523 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 3106 | 0.020 |
Why?
|
| Endothelin-1 | 1 | 2012 | 45 | 0.020 |
Why?
|
| Bleomycin | 1 | 2012 | 114 | 0.020 |
Why?
|
| Hospitalization | 1 | 2020 | 1921 | 0.020 |
Why?
|
| Purines | 1 | 2012 | 119 | 0.020 |
Why?
|
| Cell Line | 1 | 2014 | 2855 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2012 | 334 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2012 | 504 | 0.020 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2009 | 35 | 0.020 |
Why?
|
| Mucins | 1 | 2009 | 77 | 0.020 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2009 | 130 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2008 | 86 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2008 | 107 | 0.020 |
Why?
|
| Aerosols | 1 | 2008 | 65 | 0.020 |
Why?
|
| Neutrophil Infiltration | 1 | 2008 | 64 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2009 | 301 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 3418 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2009 | 285 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 2559 | 0.020 |
Why?
|
| Klebsiella Infections | 1 | 2007 | 62 | 0.020 |
Why?
|
| Klebsiella pneumoniae | 1 | 2007 | 88 | 0.020 |
Why?
|
| Action Potentials | 1 | 2009 | 521 | 0.020 |
Why?
|
| Peptide Hydrolases | 1 | 2007 | 149 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2007 | 336 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2006 | 432 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 1083 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 684 | 0.010 |
Why?
|
| Cell Survival | 1 | 2006 | 884 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2008 | 1584 | 0.010 |
Why?
|
| Neoplasms | 1 | 2019 | 2989 | 0.010 |
Why?
|
| Bacteria | 1 | 2008 | 536 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 4759 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2006 | 1041 | 0.010 |
Why?
|
| Neurons | 1 | 2009 | 2050 | 0.010 |
Why?
|
| Aged | 1 | 2016 | 21484 | 0.010 |
Why?
|